LabGenius, a pioneer in the use of machine learning (ML) for antibody engineering, today announced that it has been awarded a highly competitive SMART grant from InnovateUK. Fund grants of £ 25 million enable companies such as LabGenius to realize the potential of new ideas by investing in innovative and commercially viable research and development projects.
To date, the LabGenius platform EVA was used to co-optimize mono- and multi-specific single domain antibodies for biochemical and biofunctional properties, including stability, potency and selective killing of cancer cells.
The original text of this announcement, written in the source language, is the official version that is authentic. The translations are offered solely for the reader's convenience and must refer to the text in the original language, which is the only legally valid one.
Google DeepMind is introducing an improved version of its artificial intelligence model. The new improved model provides not only…
Laravel, famous for its elegant syntax and powerful features, also provides a solid foundation for modular architecture. There…
Cisco and Splunk are helping customers accelerate their journey to the Security Operations Center (SOC) of the future with…
Ransomware has dominated the news for the last two years. Most people are well aware that attacks…
An ophthalmoplasty operation using the Apple Vision Pro commercial viewer was performed at the Catania Polyclinic…
Developing fine motor skills through coloring prepares children for more complex skills like writing. To color…
The naval sector is a true global economic power, which has navigated towards a 150 billion market...
Last Monday, the Financial Times announced a deal with OpenAI. FT licenses its world-class journalism…
